Interesting. Abbvie now has a BD-2 selective BET inhibitor (ABBV-744) in cancer trial for mCRPC and AML. See this AACR 2018 thread on the Zenith board. Since both apabetalone and ABBV-744 are BD-2 selective BET inhibitors: 1) Will ABBV-744 be a competitor for apabetalone for MACE reduction? 2) Does apabetalone have similar anti-proliferative effects in certain cancers as observed with ABBV-744?

Also of note, BD-2 selective apabetalone (RVX-208) was shown in a recent publication in PNAS from Jay Bradner's group to not impair adipocyte differentiation. However, several pan-BET inhibitors tested (JQ1, PF-1, I-BET151, I-BET762) do impair adipocyte differentiation. From the abstract "BRD4 binds to enhancers that drive expression of PPARγ, a master transcription factor required for normal adipocyte differentiation. Disrupting BRD4 at these enhancers blocks PPARγ expression and impairs differentiation." This bodes well for apabetalone.

BDAZ